Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
57.04
+0.75 (1.33%)
At close: Jan 21, 2025, 4:00 PM
56.98
-0.06 (-0.11%)
After-hours: Jan 21, 2025, 7:57 PM EST
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.89B in the quarter ending September 30, 2024, with 8.44% growth. This brings the company's revenue in the last twelve months to $47.44B, up 5.56% year-over-year. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, down -2.50%.
Revenue (ttm)
$47.44B
Revenue Growth
+5.56%
P/S Ratio
2.44
Revenue / Employee
$1,391,056
Employees
34,100
Market Cap
115.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BMY News
- 2 days ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 6 days ago - Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
- 8 days ago - Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors - GlobeNewsWire
- 12 days ago - Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills - Seeking Alpha
- 13 days ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 18 days ago - Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference - Business Wire
- 21 days ago - Drugmakers to raise US prices on over 250 medicines starting Jan. 1 - Reuters